β-adrenoreceptor (ADRB) ligands are actively used in the therapy of bronchopulmonary and cardiovascular diseases. When using these drugs, it is important to assess changes in ADRB content in different tissues. In most cases, the direct measurement of ADRB content in lung and heart cells is not possible. ADRB2 content in peripheral blood lymphocytes (or mononuclear cells) was shown to correlate with that in myocardial cells. It has been suggested that blood lymphocytes can be used to monitor ADRB content in solid organs. However, the estimation of ADRB1 content in myocardium from its content in peripheral lymphocytes is not possible due to the low content of ADRB1 in lymphocytes. In the present study, we performed simultaneous determination of ADRB1 and ADRB2 both in the total population of PBMCs and in isolated subpopulations of monocytes, T-lymphocytes, and NK-cells from 23 healthy donors using the modified radioligand method. The highest amount of ADRB2 was detected in NK cells, followed by PBMCs, monocytes, and T cells. The content of these receptors in all blood cell subpopulations was significantly correlated with each other, suggesting the possibility of using PBMCs to monitor ADRB2 in solid organs. For the first time, ADRB1 was detected in monocytes and NK cells.
1 January 2026 in Cardiology: News, Opinions, Training
The detection of autoantibodies against the β1-adrenergic receptor (ADRB1 Ab) in the blood of patients and the monitoring of the levels of these antibodies is an urgent need in clinical practice. The solid-phase enzyme-linked immunosorbent assay (ELISA), using ADRB1 in native conformation as antigen, seems to be the most suitable for this task. We have previously tested various amphipathic polymers for their ability to solubilize ADRB1 in the form of nanodiscs so that ADRB1 retains its antigenic properties. The aim of the present work was to investigate the ligand binding properties of ADRB1 in nanodiscs prepared with amphipathic polymers such as UltrasoluteTM Amphipol (UA17) and AASTY 11-45 and to determine the size of the nanodiscs by dynamic light scattering. The binding of the ligands isoproterenol (agonist) and cyanopindolol (antagonist) was assessed by their ability to compete with recombinant hAB2367 antibodies specific for the second extracellular loop of ADRB1 in ELISA. It was found that ADRB1 solubilized with UA17 and AASTY 11-45 retained its ligand-binding properties. This fact supports the assumption that ADRB1 retains its native structure in nanodiscs. The size of nanodiscs prepared with UA17 was determined for the first time by dynamic light scattering. In the range of polymer concentrations from 0.0625% to 0.5%, no significant differences were observed in the size of the nanodiscs, which varied between 10 and 16 nm.
Background: Matrix metalloproteinase 9 (MMP9) has recently emerged as a risk predictor in patients with cardiovascular diseases (CVD). However, little is known regarding the significance of elevated plasma MMP9 levels in patients during the long-term period following myocardial revascularisation. We aimed to investigate the role of MMP9 in relation to myocardial status before and after myocardial revascularisation and to assess its long-term prognostic value. Methods: This prospective observational study included 200 male patients with ischaemic heart disease. All patients underwent direct myocardial revascularisation on a beating heart (off-pump surgery). Plasma MMP9 levels were analysed preoperatively, at 48 h postoperatively, and during the long-term follow-up period (one year postoperatively). Key echocardiographic parameters, specifically left ventricular ejection fraction (LVEF) and Left Ventricular End-Diastolic Volume (LVEDV), were also assessed. Results: MMP9 levels decreased significantly at 48 h postoperatively (p < 0.0001). During the long-term postoperative period, a clear relationship was demonstrated: higher 1-year MMP9 levels were associated with lower 1-year LVEF, whilst lower 1-year MMP9 levels were associated with higher 1-year LVEF. No significant correlation was observed between preoperative MMP9 levels and age or most other baseline laboratory parameters. Conclusions: Our study established an association between 1-year postoperative MMP9 levels and key parameters of left ventricular function during the long-term follow-up period. This suggests that MMP9 may serve as a novel biomarker for predicting outcomes following myocardial revascularisation.